# Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

> **NCT02954523** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chul Kim** · enrollment: 10 (actual)

## Conditions studied

- EGFR Gene Mutation
- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT02954523
- **Lead sponsor:** Chul Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2018-08
- **Final completion:** 2023-03-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2024-07-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954523, "Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02954523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*